Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Pinnacle Associates Ltd.

Posted by Brenda Bartman on Oct 24th, 2026

Pinnacle Associates Ltd. cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 24.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,107 shares of the specialty pharmaceutical company’s stock after selling 2,594 shares during the period. Pinnacle Associates Ltd.’s holdings in Jazz Pharmaceuticals were worth $1,877,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in shares of Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after acquiring an additional 517,514 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $60,496,000. Tri Locum Partners LP acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $29,995,000. Bank of America Corp DE raised its position in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. Finally, Boston Trust Walden Corp raised its position in Jazz Pharmaceuticals by 24.1% in the first quarter. Boston Trust Walden Corp now owns 488,661 shares of the specialty pharmaceutical company’s stock valued at $92,381,000 after purchasing an additional 94,750 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $214.00 on Friday. The firm has a 50 day moving average of $236.11 and a two-hundred day moving average of $232.83. The stock has a market capitalization of $13.89 billion, a PE ratio of 14.76, a P/E/G ratio of 0.22 and a beta of 0.37. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a 52 week low of $128.80 and a 52 week high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm’s revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($8.25) EPS. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares in the company, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $337.00 price objective on the stock. Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft raised their target price on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. Finally, Royal Bank Of Canada dropped their target price on Jazz Pharmaceuticals from $299.00 to $296.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $290.85.

Check Out Our Latest Research Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.